查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2022532

急性呼吸窘迫症候群（ARDS）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

Acute Respiratory Distress Syndrome (ARDS) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 155 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 預計義大利 ARDS 市場將從 2025 年的 6,200 萬美元成長到 2035 年的 1.22 億美元，這反映出在重症監護的進步和支持療法的增加的推動下，市場實現了中等到強勁的成長。
  • 市場成長並非僅與發病率直接相關，而是受到以下因素的影響：
  • 重症監護室高階干預措施（體外膜氧合、機械通氣等）的使用增加
  • 重症加護病房醫療成本不斷上漲
  • 目前的市場規模主要來自支持性照護基礎設施（人工呼吸器系統、ICU 管理），而非藥物治療。
  • 未來市場擴張取決於針對 ARDS 潛在發炎和血管機制的標靶治療的開發和引入。

急性呼吸窘迫症候群（ARDS）概述

急性呼吸窘迫症候群（ARDS）是嚴重的、危及生命的發炎性肺部疾病，其特徵是由於肺泡和毛細血管屏障功能破壞而導致的急性非心源性肺水腫。這會導致瀰漫性肺泡損傷（DAD）、氣體交換受損和難治性低氧血症。

ARDS通常是直接肺損傷（例如重症肺炎、吸入性肺炎）或間接全身性疾病（例如敗血症或嚴重創傷）的併發症。其病理生理機制是由不受控制的發炎級聯反應所驅動，導致血管滲透性增加、液體滲入肺泡、肺順應性下降。

診斷和嚴重程度分類是基於柏林定義，該定義根據低氧血症的程度（PaO2/FiO2 比率）以及是否存在無法用心臟衰竭或體液超負荷解釋的雙側浸潤，將 ARDS 分為輕度、中度和重度。

目前，尚無核准的針對急性呼吸窘迫症候群（ARDS）的標靶治療，治療仍以支持性治療為主。標準治療包括肺保護性機械呼吸系統護理（低潮氣量、最佳化呼氣末正壓通氣）、保守的液體管理、預防人工呼吸器相關性肺損傷（VILI）。在重症病例中，會採用俯臥通氣、神經肌肉阻斷和靜脈-靜脈體外膜氧合（VV-ECMO）等高階干預措施來改善氧合和提高存活率。

主要亮點

  • 在美國，預計 2025 年 ARDS 新發病例數將增加到 2035 年的 547,300 例，增幅為 586,700 例，這反映出由於人口老化和嚴重發病率上升而導致的逐漸成長（年複合成長率為 0.7%）。
  • 儘管盛行率很高，但治療仍然完全是支持性的，沒有核准的疾病修正治療，這代表著一個重大的未滿足需求。
  • 人們越來越關注抗發炎療法、內皮細胞穩定療法和再生療法的研究，預計這將塑造未來的治療模式。

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Changchun Tuohua Pharmaceutical Co., Ltd.
  • Breathe Biologics, Inc.
  • Staidson（Beijing）Biopharmaceuticals Co., Ltd.
  • EnliTISA（Shanghai）Pharmaceutical Co., Ltd.
  • HTIC, Inc
  • BioAegis Therapeutics Inc.
  • Direct Biologics, LLC
  • Implicit Bioscience
  • Dompe Farmaceutici SpA
  • Pharmazz, Inc.
  • Aqualung Therapeutics Corp.
  • Arch Biopartners Inc.
  • Vasomune Therapeutics, Inc.
  • ImmunityBio, Inc.
  • AVM Biotechnology Inc

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並接受藥物治療的患者人數
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
  • 新興治療方法
  • 重點
  • 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
  • 值得關注的早期管道

第6章：未滿足的需求與目標產品分析

  • 主要未滿足的需求以及透過新興治療方法實現的未來可能性
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Acute Respiratory Distress Syndrome (ARDS) Market Outlook

Thelansis's "Acute Respiratory Distress Syndrome (ARDS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Respiratory Distress Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Acute Respiratory Distress Syndrome (ARDS) Overview

Acute Respiratory Distress Syndrome (ARDS) is a severe, life-threatening inflammatory lung condition characterized by acute, non-cardiogenic pulmonary edema resulting from disruption of the alveolar-capillary barrier. This leads to diffuse alveolar damage (DAD), impaired gas exchange, and refractory hypoxemia.

ARDS typically arises as a complication of direct pulmonary insults (e.g., severe pneumonia, aspiration) or indirect systemic conditions such as Sepsis and major trauma. The pathophysiology is driven by an uncontrolled inflammatory cascade, leading to increased vascular permeability, alveolar flooding, and loss of lung compliance.

Diagnosis and severity classification are based on the Berlin Definition, which stratifies ARDS into mild, moderate, and severe categories according to the degree of hypoxemia (PaO2/FiO2 ratio) and the presence of bilateral infiltrates not explained by cardiac failure or fluid overload.

There are currently no approved targeted pharmacological therapies for ARDS, and management remains entirely supportive. Standard of care relies on lung-protective mechanical ventilation strategies (low tidal volume, optimized PEEP), conservative fluid management, and prevention of ventilator-induced lung injury (VILI). In severe cases, advanced interventions such as prone positioning, neuromuscular blockade, and venovenous extracorporeal membrane oxygenation (VV-ECMO) are utilized to improve oxygenation and survival outcomes.

Key Highlights

  • In the US, incident ARDS cases are projected to increase from 547.3K in 2025 to 586.7K by 2035, reflecting a modest growth trajectory (0.7% CAGR) linked to aging population and rising critical illness incidence.
  • Despite high incidence, treatment remains entirely supportive, with no approved disease-modifying therapies, representing a major unmet clinical need.
  • Increasing research focus on anti-inflammatory, endothelial-stabilizing, and regenerative therapies is expected to shape future treatment paradigms.

Market Overview

  • The ARDS market in Italy is projected to grow from $62M in 2025 to $122M by 2035, reflecting moderate-to-strong growth driven by critical care advancements and supportive therapy utilization.
  • Market growth is not directly correlated with incidence alone but influenced by:
  • Increased use of advanced ICU interventions (e.g., ECMO, ventilation technologies)
  • Rising healthcare expenditure in critical care settings
  • Current market value is largely derived from supportive care infrastructure (ventilation systems, ICU management), rather than pharmacological therapies.
  • Future market expansion will depend on the development and adoption of targeted therapies addressing the underlying inflammatory and vascular mechanisms of ARDS.

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Changchun Tuohua Pharmaceutical Co., Ltd.
  • Breathe Biologics, Inc.
  • Staidson (Beijing) Biopharmaceuticals Co., Ltd.
  • EnliTISA (Shanghai) Pharmaceutical Co., Ltd.
  • HTIC, Inc
  • BioAegis Therapeutics Inc.
  • Direct Biologics, LLC
  • Implicit Bioscience
  • Dompe Farmaceutici S.p.A
  • Pharmazz, Inc.
  • Aqualung Therapeutics Corp.
  • Arch Biopartners Inc.
  • Vasomune Therapeutics, Inc.
  • ImmunityBio, Inc.
  • AVM Biotechnology Inc

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)